Rockwell Medical
Market Cap
US$170.6m
Last Updated
2020/02/16 23:51 UTC
Data Sources
Company Financials +
Executive Summary
Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has Rockwell Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RMTI has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
16.0%
RMTI
2.4%
US Medical Equipment
1.8%
US Market
1 Year Return
-40.2%
RMTI
22.1%
US Medical Equipment
20.1%
US Market
Return vs Industry: RMTI underperformed the US Medical Equipment industry which returned 22.1% over the past year.
Return vs Market: RMTI underperformed the US Market which returned 20.1% over the past year.
Shareholder returns
| RMTI | Industry | Market | |
|---|---|---|---|
| 7 Day | 16.0% | 2.4% | 1.8% |
| 30 Day | -2.3% | 1.2% | 1.4% |
| 90 Day | 23.9% | 8.6% | 8.8% |
| 1 Year | -40.2%-40.2% | 23.0%22.1% | 22.7%20.1% |
| 3 Year | -57.7%-57.7% | 84.6%79.4% | 50.1%40.4% |
| 5 Year | -76.3%-76.3% | 117.3%94.6% | 72.9%53.9% |
Price Volatility Vs. Market
How volatile is Rockwell Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Rockwell Medical, Inc. (NASDAQ:RMTI): Is Breakeven Near?1 month ago | Simply Wall St
Should You Be Concerned About Rockwell Medical, Inc.'s (NASDAQ:RMTI) Historical Volatility?2 months ago | Simply Wall St
Introducing Rockwell Medical (NASDAQ:RMTI), The Stock That Tanked 73%Valuation
Is Rockwell Medical undervalued compared to its fair value and its price relative to the market?
6.85x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RMTI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RMTI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RMTI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: RMTI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RMTI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RMTI is overvalued based on its PB Ratio (6.8x) compared to the US Medical Equipment industry average (4x).
Next Steps
Future Growth
How is Rockwell Medical forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
57.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RMTI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: RMTI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RMTI's is expected to become profitable in the next 3 years.
Revenue vs Market: RMTI's revenue (23.4% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: RMTI's revenue (23.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RMTI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Rockwell Medical performed over the past 5 years?
-16.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RMTI is currently unprofitable.
Growing Profit Margin: RMTI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RMTI is unprofitable, and losses have increased over the past 5 years at a rate of -16.4% per year.
Accelerating Growth: Unable to compare RMTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RMTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.1%).
Return on Equity
High ROE: RMTI has a negative Return on Equity (-152.73%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Rockwell Medical's financial position?
Financial Position Analysis
Short Term Liabilities: RMTI's short term assets ($40.6M) exceed its short term liabilities ($12.4M).
Long Term Liabilities: RMTI's short term assets ($40.6M) exceed its long term liabilities ($12.0M).
Debt to Equity History and Analysis
Debt Level: RMTI's debt to equity ratio (4.8%) is considered satisfactory.
Reducing Debt: RMTI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Inventory Level: RMTI has a low level of unsold assets or inventory.
Debt Coverage by Assets: RMTI's debt is covered by short term assets (assets are 35.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RMTI has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: RMTI has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.9% each year.
Next Steps
Dividend
What is Rockwell Medical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate RMTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RMTI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RMTI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RMTI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RMTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.3yrs
Average management tenure
CEO
Stuart Paul (59yo)
1.4yrs
Tenure
US$7,483,803
Compensation
Mr. Stuart Paul has been Chief Executive Officer and Director at Rockwell Medical, Inc. since September 04, 2018 and also serves as it's President. He served as the President of Asia & Pacific (APAC) at Ga ...
CEO Compensation Analysis
Compensation vs Market: Stuart's total compensation ($USD7.48M) is above average for companies of similar size in the US market ($USD1.11M).
Compensation vs Earnings: Insufficient data to compare Stuart's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.4yrs | US$7.48m | 0.20% $347.9k | |
| Chief Financial Officer | 1.3yrs | US$1.45m | 0.044% $75.2k | |
| Chief Scientific Officer & Member of Scientific Advisory Board | 14.3yrs | US$954.42k | 0.83% $1.4m | |
| Vice President of Operations | 1.2yrs | no data | no data | |
| VP, Corporate Controller & Principal Accounting Officer | 0.7yrs | no data | no data | |
| General Counsel | 0yrs | no data | no data | |
| Senior Vice President of Business & Corporate Development | 1.4yrs | no data | no data | |
| Vice President of Sales and Strategic Accounts | 1.3yrs | no data | no data | |
| Chief Development Officer | 7.8yrs | US$965.87k | 0.47% $807.6k | |
| Executive Officer | 0.7yrs | no data | 0.0049% $8.3k |
1.3yrs
Average Tenure
55.5yo
Average Age
Experienced Management: RMTI's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.4yrs | US$7.48m | 0.20% $347.9k | |
| Chief Scientific Officer & Member of Scientific Advisory Board | 14.3yrs | US$954.42k | 0.83% $1.4m | |
| Independent Director | 2.4yrs | US$286.19k | no data | |
| Independent Director | 1.9yrs | US$246.15k | no data | |
| Chairman | 0.3yrs | no data | no data | |
| Member of Medical Advisory Board | 14.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 14.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.1yrs | no data | no data |
8.0yrs
Average Tenure
61yo
Average Age
Experienced Board: RMTI's board of directors are considered experienced (8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.3%.
Top Shareholders
Company Information
Rockwell Medical, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Rockwell Medical, Inc.
- Ticker: RMTI
- Exchange: NasdaqGM
- Founded: 1994
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$170.554m
- Shares outstanding: 67.15m
- Website: https://www.rockwellmed.com
Number of Employees
Location
- Rockwell Medical, Inc.
- 30142 Wixom Road
- Wixom
- Michigan
- 48393
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RMTI | NasdaqGM (Nasdaq Global Market) | Yes | Common Shares | US | USD | Jan 1998 |
| RWM | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jan 1998 |
Biography
Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis. It is also developing an intravenous formulation of Triferic for use by hemodialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. Its target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1994 and is based in Wixom, Michigan.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/16 23:51 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.